Murine xenograft model demonstrates significant radio-sensitising effect of liposomal doxorubicin in a combination therapy for Feline Injection Site Sarcoma
Autor: | H. Petznek, Alexander Tichy, Miriam Kleiter, C. Hohenadl, Andrea Fuchs-Baumgartinger |
---|---|
Rok vydání: | 2014 |
Předmět: |
Male
Pathology medicine.medical_specialty Programmed cell death Time Factors Combination therapy medicine.medical_treatment Transplantation Heterologous Mice Nude In Vitro Techniques Cat Diseases Polyethylene Glycols Mice In vivo Cell Line Tumor medicine Animals Doxorubicin Neoplasms Connective Tissue Antibiotics Antineoplastic Dose-Response Relationship Drug Radiotherapy General Veterinary business.industry Sarcoma medicine.disease Combined Modality Therapy Xenograft Model Antitumor Assays Radiation therapy Disease Models Animal Treatment Outcome Concomitant Cats Cancer research Female business Adjuvant medicine.drug |
Zdroj: | Research in Veterinary Science. 97:386-390 |
ISSN: | 0034-5288 |
DOI: | 10.1016/j.rvsc.2014.07.008 |
Popis: | Therapy of cats suffering from feline injection site sarcomas (FISS) is still a challenging problem, as the recurrence rate after surgery is up to 70%. Four FISS-derived primary tumour cell lines and corresponding xenograft tumour mouse models were established to evaluate the efficacy of a concomitant chemo-/radiation therapy with doxorubicin. In vitro, strongly depending upon the timing of administration, pre-treatment with 0.25 µmol doxorubicin resulted in a significant enhancement of radiation-induced (3.5 Gy) tumour cell death. This result was confirmed in vivo, where only the combined chemo-/radiation therapy resulted in a significant reduction in tumour growth compared to the respective mono-therapies with either doxorubicin or radiation. These results support the use of the concomitant chemo-/radiation therapy for adjuvant treatment of FISS, particularly in advanced or recurrent disease where surgery alone is no longer feasible. |
Databáze: | OpenAIRE |
Externí odkaz: |